Prodromal DEtErminants for PhENoconversion of idiopathic RBD to alpha-synucleinopathies (PD, DLB and MSA)
Lombady partners:
- Graziella Cappelletti Università degli Studi di Milano
- Beatrice De Maria IRCCS Istituti Clinici Scientifici Maugeri Spa SB
|
Pathology of interest: |
Idiopathic REM sleep behavior disorder (iRBD) |
|
Area of research: |
Parkinson’s disease |
|
Start date: |
1 February 2023 |
|
End date: |
31 January 2026 |
|
Funding: |
€ 490.980,00 |
|
Project partners: |
Università degli Studi di Milano, Italy University of Luxembourg, Translational Neuroscience, Luxembourg Center for Systems Biomedicine (LCSB), Luxembourg IRCCS Istituti Clinici Scientifici Maugeri, Italy Lund University, Dept. Experimental Medical Science, Sweden Commissariat a l’Energie Atomique et aux énergies alternatives, Institut Francois Jacob (MIRCen), CEA and Laboratory of Neurodegenerative Diseases, CNRS, France University of Copenhagen, Dept.Drug Design andPharmacology,Denmark The Danish Parkinson’s Association, Denmark University of Zagreb, School of Medicine, Dept.Social Medicine and Organization of Healthcare, School of Public Health, Croatia |
Evidence shows that individuals affected by idiopathic REM sleep behavior disorder (iRBD) have a high risk of conversion to Parkinson’s disease, or dementia with Lewy bodies, or multiple system atrophy. Despite sharing a cellular pathological hallmark, the aggregation of alpha-synuclein, and some clinical features in the early stages, these conditions show different phenotypes in later stages with significant therapeutic and prognostic consequences for the patients. The consortium DEEPEN-iRBD aims to develop a pathogenicity model for prediction of phenoconversion utilizing pre-clinical/clinical research and data analysis, taking into account a personalised medicine approach, based on the individual’s unique characteristics and optimisation of strategies for the prevention, diagnosis and treatment of the individuals rather than the disease. In this project, both existing and newly acquired data will be integrated, including advanced clinical assessments, physiological signal recordings, molecular markers derived from body fluids, skin biopsy, and iPSCderived brain cells, in order to identify a specific profile at a very early stage, that is a prodromal phase, for each of the above conditions. This would ultimately allow to define a model for early risk stratification, diagnosis, treatment, and prognosis of patients with iRBD. A further important objective of the project deals with the ethical and social aspects of screening people in a prodromal stage of the diseases and of communicating the screening results.